Eyetelligence develops AI-enabled software and hardware that uses retinal imaging to screen for eye and systemic health conditions. Its suite of clinically validated, regulatory-approved products is already in use in Australia, New Zealand, Europe, and Japan. The company sells through partners including Bupa Optical and George & Matilda. Eyetelligence plans to rebrand and launch in the U.S. as Optain to offer non-invasive point-of-care diagnostics aimed at faster, more cost-effective disease detection. The Ascertain investment will support expansion into American markets while Eyetelligence continues to operate under its existing brand in Australia and other international markets. The company framed the move as accelerating a shift from reactive sick-care to proactive preventive care.

Total raised

$12M

Funding rounds

1

Latest round

Equity

Latest activity

May 2023